Evidence map›Paper›PMID 26730290›Full record

ReviewWorld journal of cardiology2015

Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction.

Christian Schulte, Dirk Westermann, Stefan Blankenberg, Tanja Zeller

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. AnCurrent diabetes reviews · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Specific microRNAs and heart failure: time for the next step toward application?Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. MicroRNA and Cardiovascular DiseasesBalkan medical journal · 2020
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Redefining biomarkers in heart failure.Heart failure reviews · 2018
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Christian SchulteChristian Schulte, Dirk Westermann, Stefan Blankenberg, Tanja Zeller, Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, 20246 Hamburg, Germany.
Dirk WestermannChristian Schulte, Dirk Westermann, Stefan Blankenberg, Tanja Zeller, Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, 20246 Hamburg, Germany.
Stefan BlankenbergChristian Schulte, Dirk Westermann, Stefan Blankenberg, Tanja Zeller, Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, 20246 Hamburg, Germany.
Tanja ZellerChristian Schulte, Dirk Westermann, Stefan Blankenberg, Tanja Zeller, Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, 20246 Hamburg, Germany.
Universität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

microRNAs (miRNAs) are powerful regulators of posttranscriptional gene expression and play an important role in pathophysiological processes. Circulating miRNAs can be quantified in body liquids and are promising biomarkers in numerous diseases. In cardiovascular disease miRNAs have been proven to be reliable diagnostic biomarkers for different disease entities. In cardiac fibrosis (CF) and heart failure (HF) dysregulated circulating miRNAs have been identified, indicating their promising applicability as diagnostic biomarkers. Some miRNAs were successfully tested in risk stratification of HF implementing their potential use as prognostic biomarkers. In this respect miRNAs might soon be implemented in diagnostic clinical routine. In the young field of miRNA based research advances have been made in identifying miRNAs as potential targets for the treatment of experimental CF and HF. Promising study results suggest their potential future application as therapeutic agents in treatment of cardiovascular disease. This article summarizes the current state of the various aspects of miRNA research in the field of CF and HF with reduced ejection fraction as well as preserved ejection fraction. The review provides an overview of the application of circulating miRNAs as biomarkers in CF and HF and current approaches to therapeutically utilize miRNAs in this field of cardiovascular disease.

Indexed as

BiomarkerCardiac fibrosisDiagnosticHeart failureHeart failure with preserved ejection fractionHeart failure with reduced ejection fractionMicroRNAPrognostic

Identifiers

PMID26730290
PMCPMC4691811
OpenAlexW2418943961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.